Tumor Necrosis Factors (TNF)-α Blockade for Psoriatic Arthritis

Psoriatic Arthritis Clinical Trial

Official title:

TNF-α Blockade for Psoriatic Arthritis - A Clinical and MRI Study, and the Effects on Cytokine and Cardiovascular Risk Profile

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00432406
• Other study ID #: PSA-2006-002
• Status: Completed
• Phase: Phase 4
• First received: February 6, 2007
• Last updated: March 10, 2009
• Start date: May 2006
• Est. completion date: March 2009

Study information

• Verified date: March 2009
• Source: Chinese University of Hong Kong
• Contact: n/a
• Is FDA regulated: No
• Health authority: Hong Kong: Department of Health
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is:

• To elucidate the immunomodulating properties of anti-TNF-α therapy in patients with psoriatic arthritis (PsA).

• To ascertain whether magnetic resonance imaging (MRI) is a sensitive tool in measuring early response after therapy with anti-TNF-α in the PsA wrist using the Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) guidelines for rheumatoid arthritis (RA).

• To assess whether the lipid and other cardiovascular risk profiles would improve after anti-TNF-α therapy in patients with PsA.

Description:

The study was a 12-week, open-label trial of anti-TNF therapy in 20 consecutive patients (Group 1). Another 20 consecutive patients with active disease whom have met the exclusion criteria, or were unwilling to start anti-TNF therapy for fear of toxicity would be recruited as control patients (Group 2). 20 healthy controls were recruited for comparison of the metabolic risk factors (Group 3). Study visits for groups 1 and 2 were conducted at baseline, weeks 2 and 6, and then week 12.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: March 2009
• Est. primary completion date: March 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Age 18 or above

• PsA with active disease despite treatment with non-steroidal anti-inflammatory drug (NSAID)

• 3 or more swollen and tender joints

• Inadequate response after 4 weeks of, or intolerance to nonsteroidal anti-inflammatory drug therapy.

• Methotrexate (MTX) is allowed during the study only if it has been taken for at least 3 months previously, with the dosage stable for at least 4 weeks prior to the baseline visit.

• Prednisone = 10 mg/day and/or nonsteroidal anti-inflammatory drugs must have been taken at stable dosage for at least 2 weeks before entering the trial.

• Informed consent

Exclusion Criteria:

• Little or no ability for self-care

• Used a DMARD other than methotrexate or received intra-articular, intramuscular, or intravenous corticosteroids in the 4 weeks before screening.

• Topical vitamin A (Neotigason CR) or D analog preparations (Daivonex CR), and anthralin for psoriasis within 2 weeks of baseline.

• Concurrent treatment with MTX at dosages > 15 mg/week and/or corticosteroids in a prednisone-equivalent dosage of > 10 mg/day.

• Prior anti-TNF therapy at any time.

• Infected joint prosthesis during the previous 5 years.

• Serious infections, such as hepatitis, pneumonia, pyelonephritis in the previous 3 months.

• Any chronic infectious disease such as renal infection, chest infection with bronchiectasis or sinusitis.

• Active tuberculosis requiring treatment within the previous 3 years.

• Opportunistic infections such as herpes zoster within the previous 2 months.

• Any evidence of active cytomegalovirus; active Pneumocystis carinii; or drug-resistant atypical mycobacterial infection.

• Known hypersensitivity to murine proteins

• Current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, haematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological, or cerebral disease.

• A history of lymphoproliferative disease including lymphoma or signs suggestive of disease, such as lymphadenopathy of unusual size or location (ie, lymph nodes in the posterior triangle of the neck, infraclavicular epitrochlear, or periaortic areas); splenomegaly.

• Any known malignant disease except basal cell carcinoma currently or in the past 5 years.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Psoriatic
• Psoriatic Arthritis

Intervention

Drug:
• Infliximab
Infliximab 5 mg/kg given at day 1, week 2, week 6
• Etanercept
Etanercept 25 mg twice weekly

Locations

Country	Name	City	State
China	Prince of Wales Hospital	Hong Kong

Sponsors (1)

Lead Sponsor	Collaborator
Chinese University of Hong Kong

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in the degree of inflammation as reflected by the MRI score, cytokines and chemokine levels		week 52	Yes
Primary	Changes in the cardiovascular risk factor levels which are directly mediated by TNF-a		week 52	Yes
Secondary	Number of patients who can achieve ACR 20		week 52	Yes
Secondary	Correlation of clinical parameter, inflammatory markers and MRI findings		week 52	Yes